To explore whether p181-tau measurements and/or tau measured using our FL and mid-region assays could discriminate between AD and healthy controls (HC), we divided (post hoc) the 40 samples analyzed in our study into three diagnostic groups (HC, MCI, and AD) and compared the concentrations of tau analytes across the groups. Here, MAPT is linked to Alzheimer disease.